doi: 10.1136/bmj.i575.
Rivaroxaban: can we trust the evidence?
- PMID: 26843102
- DOI: 10.1136/bmj.i575
Item in Clipboard
Rivaroxaban: can we trust the evidence?
BMJ.
.
No abstract available
Comment in
-
Questions about the reliability of ROCKET-AF anticoagulation data.BMJ. 2016 Feb 23;352:i1039. doi: 10.1136/bmj.i1039. BMJ. 2016. PMID: 26908261 No abstract available.
-
Quality control of point of care INR devices is essential.BMJ. 2016 Apr 12;353:i2019. doi: 10.1136/bmj.i2019. BMJ. 2016. PMID: 27071995 No abstract available.
Similar articles
-
Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device.BMJ. 2015 Dec 3;351:h6431. doi: 10.1136/bmj.h6431. BMJ. 2015. PMID: 26635138 No abstract available.
-
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.Am J Cardiovasc Drugs. 2015 Dec;15(6):395-401. doi: 10.1007/s40256-015-0127-2. Am J Cardiovasc Drugs. 2015. PMID: 26062914 Review.
-
The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.Int J Cardiol. 2015 Aug 1;192:1-2. doi: 10.1016/j.ijcard.2015.04.240. Epub 2015 May 1. Int J Cardiol. 2015. PMID: 25981569 No abstract available.
-
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666. Circulation. 2017. PMID: 28264892 No abstract available.
-
Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician.J Am Board Fam Med. 2015 Jul-Aug;28(4):510-22. doi: 10.3122/jabfm.2015.04.140297. J Am Board Fam Med. 2015. PMID: 26152444 Review.
Cited by
-
Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.Blood. 2021 May 20;137(20):2745-2755. doi: 10.1182/blood.2020008698. Blood. 2021. PMID: 33512454 Free PMC article.
-
Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies.J Clin Med. 2019 Apr 24;8(4):554. doi: 10.3390/jcm8040554. J Clin Med. 2019. PMID: 31022899 Free PMC article. Review.
-
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.BMC Cardiovasc Disord. 2017 Sep 6;17(1):238. doi: 10.1186/s12872-017-0672-5. BMC Cardiovasc Disord. 2017. PMID: 28874129 Free PMC article.
-
ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.Eur Heart J Suppl. 2017 May;19(Suppl D):D102-D112. doi: 10.1093/eurheartj/sux027. Epub 2017 May 2. Eur Heart J Suppl. 2017. PMID: 28751838 Free PMC article.
-
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.J Comp Eff Res. 2017 Sep;6(6):549-560. doi: 10.2217/cer-2017-0025. Epub 2017 Jul 24. J Comp Eff Res. 2017. PMID: 28737102 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
